“…Thirty-seven tissues are known to possess a VDR, the expression of which, coupled with the increased evidence involving VDR in processes other than mineral homeostasis, has prompted the generation and testing of therapeutic VDR ligands in inflammation, dermatological conditions, osteoporosis, cancers, secondary hyperparathyroidism, and autoimmune diseases (Corbett et al, 2006;Norman, 2008). These efforts have led to the development of VDR ligands for the treatment of psoriasis, secondary hyperparathyroidism, and osteoporosis (Nagpal et al, 2005).…”